Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $120M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | Visionary ... | visionaryv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.04.2022 | - | $120M | - |
Mentions in press and media 7
| Date | Title | Description |
| 07.11.2022 | Tech Moves: Allen Institute hires COO; DexCare adds CTO; and more | Chris Beaudoin, the incoming chief operating officer at the Allen Institute. (Allen Institute Photo) — The Allen Institute appointed Chris Beaudoin as its new chief operations officer. Beaudoin was previously chief operating officer at Swed... |
| 18.04.2022 | Digital health news, funding roundup in the prior week; April 18, 2022 | Carbon Health unveils diabetes solution; Northwell and Aegis team up for AI in healthcare Top Health News Northwell Health, a nonprofit integrated healthcare network, and Aegis Ventures, a startup studio, partnered to form a joint venture t... |
| 16.04.2022 | Aurion Biotech Raises $120M in Funding | Aurion Biotech, a Seattle, WA, Boston, MA- and Tokyo, Japan-based clinical-stage biotech company, raised $120M in funding. The round was led by Deerfield Management, with participation from Petrichor Healthcare Capital Management, Flying L ... |
| 13.04.2022 | Aurion Biotech secures $120M | Aurion Biotech has raised $120 million in a round led by Deerfield Management. The company is a developer of regenerative therapies for patients suffering from ocular diseases like corneal endothelial disease. View round |
| 12.04.2022 | Eyes on the prize: Aurion Biotech raises $120M for 'global transformation in the cornea' | Aurion Biotech is setting its sights high with a mission to restore vision for millions of patients via regenerative therapies and a $120 million financing round to back the tech. The clinical-stage biotech’s first candidate is a cell thera... |
| 12.04.2022 | Cell therapy biotech raises $120M to advance therapy to treat common cornea condition | Hazy vision is a symptom of corneal edema secondary to endothelial dysfunction. (Aurion Biotech Image) Aurion Biotech has raised $120 million to advance its cell therapy for an eye disorder that affects millions of people. The startup is a ... |
| - | The 24-slide presentation a first-time CEO used to raise $120 million to cure blindness | Photo_Concepts/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Aurion Biotech is developing cell therapy treatments to cure blindness. The Boston and Seattle startup just rai... |